<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265395</url>
  </required_header>
  <id_info>
    <org_study_id>P03685</org_study_id>
    <secondary_id>SUCCESS</secondary_id>
    <nct_id>NCT00265395</nct_id>
  </id_info>
  <brief_title>Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)</brief_title>
  <official_title>A Study to Assess Treatment With PEG-Intron® and Rebetol® in Naïve Patients With Genotype 1 Chronic Hepatitis C and Slow Virological Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a controlled, randomized, parallel-groups, open-label, multinational study designed&#xD;
      to evaluate the efficacy and safety of PEG-Intron® (pegylated interferon alfa-2b) plus&#xD;
      Rebetol® (ribavirin) in subjects with chronic hepatitis C. It is designed to evaluate whether&#xD;
      72 weeks of treatment with PEG-Intron plus Rebetol is more effective than 48 weeks of&#xD;
      treatment in subjects with Genotype 1 chronic hepatitis C who exhibit a slow response to&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.</measure>
    <time_frame>48 or 72 weeks of treatment plus 24 weeks of follow-up.</time_frame>
    <description>LLQ = 30 IU/mL by reverse transcription polymerase chain reaction (RT-PCR) (Taqman Roche)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1428</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Slow responders (defined as being polymerase chain reaction [PCR] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)</intervention_name>
    <description>Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks&#xD;
200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks</description>
    <arm_group_label>Standard therapy</arm_group_label>
    <other_name>(a) SCH 54031; PEG-Intron; PegIntron; ViraferonPeg.</other_name>
    <other_name>(b) SCH 18908; Rebetol; REBETOL.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of pegylated interferon alfa-2b and ribavirin</intervention_name>
    <description>Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.&#xD;
200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks</description>
    <arm_group_label>Extended therapy</arm_group_label>
    <other_name>(a) SCH 54031; PEG-Intron; PegIntron; ViraferonPeg.</other_name>
    <other_name>(b) SCH 18908; Rebetol; REBETOL.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects aged 18 to 70 years, of either sex.&#xD;
&#xD;
          -  Genotype-1 hepatitis C virus (HCV)-ribonucleic acid (RNA)-positive subjects.&#xD;
&#xD;
          -  Subjects must be willing to give written informed consent and able to adhere to dosing&#xD;
             and visit schedules.&#xD;
&#xD;
          -  Confirmation of liver biopsy availability: Availability of a liver biopsy performed&#xD;
             within 18 months prior to the Screen visit, with a pathology report confirming the&#xD;
             histological diagnosis of chronic hepatitis or liver cirrhosis.&#xD;
&#xD;
          -  Compensated liver disease with the following minimum hematological, biochemical, and&#xD;
             serological criteria at the screen visit (WNL = within normal limits, ULN = Upper&#xD;
             Limit Normal):&#xD;
&#xD;
               -  Hemoglobin values of equal or more than 12 g/dL for females and 13 g/dL for&#xD;
                  males.&#xD;
&#xD;
               -  White blood cells (WBCs) equal to or more than 3,000/mm^3&#xD;
&#xD;
               -  Neutrophil count equal to or more than 1,500/mm^3&#xD;
&#xD;
               -  Platelet count equal to or more than 80,000/mm^3&#xD;
&#xD;
               -  Direct bilirubin up to 10% above ULN is acceptable.&#xD;
&#xD;
               -  Indirect bilirubin up to 10% above ULN is acceptable (unless non-hepatitis&#xD;
                  related factors such as Gilbert's disease explain an indirect bilirubin rise). In&#xD;
                  such cases indirect bilirubin should be less than or equal to 3.0 mg/dL (less&#xD;
                  than or equal to 51.3 µmol/L)&#xD;
&#xD;
               -  Albumin up to 10% above ULN is acceptable.&#xD;
&#xD;
               -  Serum creatinine up to 10% above ULN is acceptable.&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) level above ULN at Screen.&#xD;
&#xD;
          -  At the Screen Visit, fasting glucose must be 70-140 mg/dL. Results between 116-140&#xD;
             mg/dL require repeat fasting glucose to be less than 140 mg/dL and HbA1C less than or&#xD;
             equal to 8.5%. HbA1C must be less than or equal to 8.5% in diabetic subjects (whether&#xD;
             on medication or diet controlled).&#xD;
&#xD;
          -  Antinuclear antibodies (ANA) must be less than or equal to 1:320.&#xD;
&#xD;
          -  Thyroid Stimulating Hormone (TSH) WNL whether in euthyroid subjects or subjects&#xD;
             requiring medical treatment. (subjects requiring medication to maintain TSH levels&#xD;
             within normal limits are eligible if all other inclusion/exclusion criteria are met).&#xD;
&#xD;
          -  Confirmation by the principal investigator or a sub-investigator that sexually active&#xD;
             females of childbearing potential are practicing adequate contraception.&#xD;
&#xD;
          -  Female subjects cannot be pregnant or breastfeeding and must be either postmenopausal,&#xD;
             surgically sterile or using 2 methods of birth control. While abstinence from sexual&#xD;
             activity is the only certain method to prevent pregnancy, female patients of&#xD;
             childbearing potential who are or who anticipate the possibility of becoming sexually&#xD;
             active with a male partner must use a combination of the following 2 methods :&#xD;
&#xD;
               -  Contraceptive pill or intrauterine device (IUD) or depot hormonal preparation&#xD;
                  (ring, injection implant) and&#xD;
&#xD;
               -  A barrier method of contraception such as diaphragm, sponge with spermicide,&#xD;
                  condom, or a method of birth control considered acceptable by the study&#xD;
                  physician. Contraceptive measures will be reviewed with female subjects at each&#xD;
                  visit. Dual methods of contraception must be used for 1 month prior to the start&#xD;
                  of treatment and 6 months after treatment discontinuation.&#xD;
&#xD;
          -  A serum pregnancy test obtained at Screen Visit prior to the initiation of treatment&#xD;
             must be negative.&#xD;
&#xD;
          -  Confirmation by the principal investigator or a sub-investigator that sexually active&#xD;
             male subjects are practicing a method of contraception considered acceptable&#xD;
             (vasectomy, condom plus spermicide, plus relationship with a female partner who&#xD;
             practices an acceptable method of contraception). Contraception must be used during&#xD;
             the treatment period and for seven months (or 6 months, according to local label)&#xD;
             after the completion of therapy, including condom use by male subjects with pregnant&#xD;
             partners.&#xD;
&#xD;
          -  For subjects with a history of hypertension or diabetes, written clearance from an&#xD;
             ophthalmologist has to be obtained prior to treatment start.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, women who plan to become pregnant, male subjects whose partner wants&#xD;
             to become pregnant, and breastfeeding women.&#xD;
&#xD;
          -  Previous treatment for chronic hepatitis C with an antiviral or immunomodulating agent&#xD;
             or with some interferon or ribavirin product, whether alone or in combination.&#xD;
&#xD;
          -  Subjects weighing over 125 kg.&#xD;
&#xD;
          -  Suspected hypersensitivity to any interferon or ribavirin product.&#xD;
&#xD;
          -  Participation in other clinical trial within 30 days prior to screen into this study.&#xD;
&#xD;
          -  Coinfection with hepatitis B virus (HBV), human immunodeficiency virus (HIV), or both.&#xD;
&#xD;
          -  Any cause of liver disease other than chronic hepatitis C, including but not limited&#xD;
             to:&#xD;
&#xD;
               -  Hemochromatosis&#xD;
&#xD;
               -  Alpha-1 antitrypsin deficiency&#xD;
&#xD;
               -  Wilson's disease&#xD;
&#xD;
               -  Autoimmune hepatitis&#xD;
&#xD;
               -  Alcoholic liver disease&#xD;
&#xD;
               -  Non-alcoholic steatohepatitis (NASH)&#xD;
&#xD;
               -  Drug-related liver disease&#xD;
&#xD;
          -  Active malignant disease or suspicion or history of malignant disease within five&#xD;
             previous years (except for adequately treated basal cell carcinoma).&#xD;
&#xD;
          -  Known coagulation diseases such as hemophilia; hemoglobin diseases (e.g. thalassemia).&#xD;
&#xD;
          -  Known glucose 6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  Evidence of advanced liver disease such as history or presence of ascites, bleeding&#xD;
             varices, or hepatic encephalopathy.&#xD;
&#xD;
          -  Subjects with organ transplants, except for corneal or hair transplant.&#xD;
&#xD;
          -  Any known preexisting medical condition that could interfere with the subject's&#xD;
             participation in and completion of study, such as:&#xD;
&#xD;
               -  Preexisting psychiatric condition, especially moderate to severe depression, or a&#xD;
                  history of severe psychiatric disorder, such as psychosis, suicidal ideation, or&#xD;
                  suicide attempts. Severe depression includes the following:&#xD;
&#xD;
                    -  Hospitalization for depression&#xD;
&#xD;
                    -  Electroconvulsive therapy for depression, or&#xD;
&#xD;
                    -  Depression causing a prolonged absence from work or significantly altering&#xD;
                       daily functions.&#xD;
&#xD;
               -  Subjects with mild depression may be considered for entry into the study provided&#xD;
                  that a pre-treatment assessment demonstrates that the subject's emotional status&#xD;
                  is clinically stable, in which case a management plan must be formulated for the&#xD;
                  subject; this management plan will become a part of the subject's medical record.&#xD;
&#xD;
               -  Craniocerebral trauma which is not a concussion, or active seizure disorders&#xD;
                  requiring medication.&#xD;
&#xD;
               -  Clinically significant electrocardiogram (ECG) abnormalities and/or&#xD;
                  cardiovascular dysfunction within 6 previous months (e.g., angina, congestive&#xD;
                  heart failure, recent myocardial infarction, or significant arrhythmia).&#xD;
&#xD;
               -  Chronic lung disease (e.g., chronic obstructive lung disease)&#xD;
&#xD;
               -  Poorly controlled diabetes mellitus&#xD;
&#xD;
               -  Immune-mediated disease (e.g., inflammatory bowel disease [Crohn's disease,&#xD;
                  ulcerative colitis], idiopathic thrombocytopenic purpura, systemic lupus&#xD;
                  erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis)&#xD;
&#xD;
               -  Clinical gout&#xD;
&#xD;
          -  Subject is or was a substance abuser, such as alcohol (80 g/day or more), methadone,&#xD;
             intravenous(IV), oral or inhaled drugs. To be considered for inclusion into the&#xD;
             protocol, the subject must have abstained and agree to abstain from using any of the&#xD;
             above for at least 6 months. Subjects treated with buprenorphine (Subutex) who have&#xD;
             been stable for 6 months may be included.&#xD;
&#xD;
          -  Cirrhotic subjects whose ultrasound confirms hepatocellular carcinoma.&#xD;
&#xD;
          -  Any other condition that, in the investigator's opinion, could determine that&#xD;
             subject's participation in the study is not indicated or could interfere with the&#xD;
             subject's participation in and completion of study.&#xD;
&#xD;
          -  Subjacent disease that potentially would require systematic administration of steroids&#xD;
&#xD;
          -  Insulin dependent diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </removed_countries>
  <results_reference>
    <citation>Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R; SUCCESS Study Investigators. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010 Oct;52(4):1201-7. doi: 10.1002/hep.23816.</citation>
    <PMID>20683847</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>December 13, 2005</study_first_submitted>
  <study_first_submitted_qc>December 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2005</study_first_posted>
  <results_first_submitted>May 15, 2009</results_first_submitted>
  <results_first_submitted_qc>May 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 8, 2009</results_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf&#xD;
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1428 patients enrolled; 159 patients qualified as slow responders per treatment week 12 and 24 protocol-specified eligibility criteria; 159 patients were randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Therapy (48-week Treatment)</title>
          <description>Slow responders (defined as being polymerase chain reaction [PCR] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.</description>
        </group>
        <group group_id="P2">
          <title>Extended Therapy (72-week Treatment)</title>
          <description>Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Therapy (48-week Treatment)</title>
          <description>Slow responders (defined as being polymerase chain reaction [PCR] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.</description>
        </group>
        <group group_id="B2">
          <title>Extended Therapy (72-week Treatment)</title>
          <description>Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="9.9"/>
                    <measurement group_id="B2" value="46.5" spread="11.6"/>
                    <measurement group_id="B3" value="45.35" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.</title>
        <description>LLQ = 30 IU/mL by reverse transcription polymerase chain reaction (RT-PCR) (Taqman Roche)</description>
        <time_frame>48 or 72 weeks of treatment plus 24 weeks of follow-up.</time_frame>
        <population>According to the protocol, the efficacy analysis was carried out on all slow responders (ie, patients who had at least 2 log drop in HCV-RNA level at treatment week 12, and undetectable HCV-RNA at treatment week 24).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Therapy (48-week Treatment)</title>
            <description>Slow responders (defined as being polymerase chain reaction [PCR] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.</description>
          </group>
          <group group_id="O2">
            <title>Extended Therapy (72-week Treatment)</title>
            <description>Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.</title>
          <description>LLQ = 30 IU/mL by reverse transcription polymerase chain reaction (RT-PCR) (Taqman Roche)</description>
          <population>According to the protocol, the efficacy analysis was carried out on all slow responders (ie, patients who had at least 2 log drop in HCV-RNA level at treatment week 12, and undetectable HCV-RNA at treatment week 24).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6445</p_value>
            <method>Asymptotic Z-test</method>
            <param_type>SVR Rate Difference</param_type>
            <param_value>-4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-20.4</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Therapy (48-week Treatment)</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK SECOND DEGREE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>AUTOIMMUNE THYROIDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>THYROIDITIS SUBACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>RETINAL TEAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>VISUAL DISTURBANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>INTUSSUSCEPTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PANCREATITIS NECROTISING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>VOLVULUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>ABSCESS ORAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>INJECTION SITE CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SALMONELLOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SYPHILIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DISLOCATION OF VERTEBRA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DRUG TOXICITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>MULTIPLE DRUG OVERDOSE INTENTIONAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SCAPULA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ARTERIOGRAM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HEART RATE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>UNEQUAL LIMB LENGTH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PARATHYROID TUMOUR BENIGN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CAROTID ARTERY DISSECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PARKINSONISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SYNCOPE VASOVAGAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, AUDITORY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, VISUAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HOMICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PARANOIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS CHRONIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HAEMOPNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>OBLITERATIVE BRONCHIOLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ECZEMA NUMMULAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ANAL FISSURE EXCISION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1337" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="260" subjects_affected="197" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>ERYTHROPENIA</sub_title>
                <counts group_id="E1" events="96" subjects_affected="74" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="268" subjects_affected="183" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="464" subjects_affected="281" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="112" subjects_affected="94" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="152" subjects_affected="129" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="75" subjects_affected="75" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="301" subjects_affected="254" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="458" subjects_affected="402" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="204" subjects_affected="153" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="412" subjects_affected="338" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="843" subjects_affected="599" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="152" subjects_affected="143" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="169" subjects_affected="157" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="834" subjects_affected="421" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="215" subjects_affected="161" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="171" subjects_affected="106" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="169" subjects_affected="150" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="112" subjects_affected="77" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="160" subjects_affected="156" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="107" subjects_affected="103" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="235" subjects_affected="195" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="106" subjects_affected="91" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="417" subjects_affected="274" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="81" subjects_affected="77" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="128" subjects_affected="115" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="569" subjects_affected="408" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="156" subjects_affected="139" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="194" subjects_affected="178" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="213" subjects_affected="195" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="124" subjects_affected="111" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="328" subjects_affected="318" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="199" subjects_affected="188" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="290" subjects_affected="267" subjects_at_risk="1427"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="211" subjects_affected="177" subjects_at_risk="1427"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

